Madison, WI, May 31, 2018 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that its flagship product, MicroLyte® Ag Matrix,is now available to physicians and other clinicians at Rush University Medical Center in Chicago, IL.
MicroLyte® Ag Matrix is the first product of its kind to combine antimicrobial silver in a bioresorbable, synthetic matrix that allows tissue growth and does not require removal from the wound bed. Designed to be safer and more readily adherent to the varied topography of complex wound beds where potential sources of infection can sequester themselves, MicroLyte® Ag Matrixworks differently than conventional silver-impregnated wound dressings which server as crude depots of silver.
“Getting on the formulary at Rush University Medical Center is an exciting an important step in continuing to getting MicroLyte® Ag Matrixinto the marketplace where it an be used to improve outcomes for patients,” said Imbed’s President and CEO, Ankit Agarwal. “Through future collaborations at Rush and other leading medical centers we will continue to prove and expand the clinical utility of MicroLyte® Ag Matrix.”
About Imbed Biosciences, Inc.
Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation.